US Sickle Cell Gene Therapy Contracting Demo Attracting Interest From States
The US Medicaid agency says states representing more than 80% of sickle cell patients are interested in a centralized contracting program, but House Republicans want legislation, not administrative interventions, to shape value-based payment for curative therapies.
